文献速递冠心病血脂与心血管预防

急性冠脉综合征与非急性冠脉综合征患者药物洗脱支架置入后双联抗血小板治疗3、6或12个月的个体患者数据配对与网络荟萃分析:六项随机试验11 473例患者

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
PubMed 文献 · Eur Heart J · 2017-01-01

该个体患者数据配对与网络荟萃分析纳入六项随机试验共11 473例药物洗脱支架置入后接受阿司匹林联合氯吡格雷双联抗血小板治疗的患者,比较短期(≤6个月)与长期(1年)以及3个月、6个月与1年双联抗血小板治疗。结果显示,急性冠脉综合征患者中≤6个月双联抗血小板治疗与1年治疗相比心肌梗死或支架血栓风险数值上更高但未达统计学显著(HR 1.48,95%CI 0.98-2.22;P=0.059),而稳定冠心病患者两种策略风险相似(HR 0.93,95%CI 0.65-1.35;P=0.71;交互作用P=0.09)。短期双联抗血小板治疗与1年治疗相比大出血发生率更低,全因死亡率无显著差异。

要点

  • 急性冠脉综合征患者中≤6个月双联抗血小板治疗与1年治疗相比心肌梗死或支架血栓风险未达统计学显著升高(HR 1.48,95%CI 0.98-2.22;P=0.059)。
  • 稳定冠心病患者中≤6个月与1年双联抗血小板治疗的心肌梗死和支架血栓发生率相似(HR 0.93,95%CI 0.65-1.35;P=0.71)。
  • 短期双联抗血小板治疗与1年治疗相比大出血发生率更低,且全因死亡率无显著差异,无论临床表现为稳定冠心病还是急性冠脉综合征。

核心结论

  • 药物洗脱支架置入后最佳双联抗血小板治疗时长因临床表现为急性冠脉综合征或稳定冠心病而异。
  • 在本荟萃分析中,尽管入选的急性冠脉综合征患者多数相对低危,3个月双联抗血小板治疗与缺血风险增加相关,而3个月双联抗血小板治疗在稳定冠心病中似乎安全。
  • 延长双联抗血小板治疗增加出血,无论临床表现如何。
  • 需进一步研究以根据个体相对缺血与出血风险确定药物洗脱支架置入后最佳双联抗血小板治疗时长。

研究设计与样本

  • 个体患者数据配对与网络荟萃分析,比较短期(≤6个月)与长期(1年)双联抗血小板治疗以及3个月、6个月与1年双联抗血小板治疗。
  • 纳入六项随机试验,共11 473例随机患者,药物洗脱支架置入后双联抗血小板治疗由阿司匹林和氯吡格雷组成。
  • 其中6714例(58.5%)为稳定冠心病,4758例(41.5%)为急性冠脉综合征,急性冠脉综合征患者中多数(67.0%)为不稳定型心绞痛。

主要发现

  • 急性冠脉综合征患者中,≤6个月双联抗血小板治疗与1年治疗相比1年心肌梗死或支架血栓发生率数值上更高但未达统计学显著(HR 1.48,95%CI 0.98-2.22;P=0.059)。
  • 稳定冠心病患者中,≤6个月与1年双联抗血小板治疗的心肌梗死和支架血栓发生率相似(HR 0.93,95%CI 0.65-1.35;P=0.71;交互作用P=0.09)。
  • 网络荟萃分析显示,急性冠脉综合征患者中3个月双联抗血小板治疗与心肌梗死或支架血栓发生率更高相关,而6个月双联抗血小板治疗无此关联;稳定冠心病患者中未见显著差异。
  • 短期双联抗血小板治疗与1年治疗相比大出血发生率更低,无论临床表现如何。
  • 短期与长期双联抗血小板治疗的全因死亡率在稳定冠心病和急性冠脉综合征患者中均无显著差异。

关键数值与推荐

  • 主要研究结局为1年心肌梗死或明确/ probable 支架血栓的复合风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以根据个体相对缺血与出血风险确定药物洗脱支架置入后最佳双联抗血小板治疗时长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: We sought to determine whether the optimal dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) placement varies according to clinical presentation. METHODS AND RESULTS: We performed an individual patient data pairwise and network meta-analysis comparing short-term (≤6-months) versus long-term (1-year) DAPT as well as 3-month vs. 6-month vs 1-year DAPT. The primary study outcome was the 1-year composite risk of myocardial infarction (MI) or definite/probable stent thrombosis (ST). Six trials were included in which DAPT after DES consisted of aspirin and clopidogrel. Among 11 473 randomized patients 6714 (58.5%) had stable CAD and 4758 (41.5%) presented with acute coronary syndrome (ACS), the majority of whom (67.0%) had unstable angina. In ACS patients, ≤6-month DAPT was associated with non-significantly higher 1-year rates of MI or ST compared with 1-year DAPT (Hazard Ratio (HR) 1.48, 95% Confidence interval (CI) 0.98-2.22; P = 0.059), whereas in stable patients rates of MI and ST were similar between the two DAPT strategies (HR 0.93, 95%CI 0.65-1.35; P = 0.71; Pinteraction = 0.09). By network meta-analysis, 3-month DAPT, but not 6-month DAPT, was associated with higher rates of MI or ST in ACS, whereas no significant differences were apparent in stable patients. Short DAPT was associated with lower rates of major bleeding compared with 1-year DAPT, irrespective of clinical presentation. All-cause mortality was not significantly different with short vs. long DAPT in both patients with stable CAD and ACS. CONCLUSIONS: Optimal DAPT duration after DES differs according to clinical presentation. In the present meta-analysis, despite the fact that most enrolled ACS patients were relatively low risk, 3-month DAPT was associated with increased ischaemic risk, whereas 3-month DAPT appeared safe in stable CAD. Prolonged DAPT increases bleeding regardless of clinical presentation. Further study is required to identify the optimal duration of DAPT after DES in individual patients based on their relative ischaemic and bleeding risks.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017. PMID: 28110296. doi:10.1093/eurheartj/ehw627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。